CD4+ T cells have long been recognized as an important component of tumor immunotherapy, as they are capable of promoting or suppressing anti-tumor cytotoxic CD8+ T cell responses in secondary lymphoid organs or tumors, hence modulating the tumor immune microenvironment [62]. This evidence concerns the gene CD4 and neoplasm.